Abundant funding, sparse data: San Francisco startup backs 'real world' model for rare disease drug development
Rare diseases, a field of drug development where funding far outstrips research on often poorly understood conditions, can leave scientists often reinventing the wheel to engineer therapeutics.
RDMD, a San Francisco-based company, has a plan to address that impasse by serving as a conduit between the patient and the drug developer. The platform courts patients with rare diseases by helping them access medical records and participate in research, while for drug developers, the company structures the compiled data in an effort to build research programs and develop an evidence base palatable for regulatory authorities.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.